Bo Zhang, Xiang Chen, Feng Ru, Yu Gan, Bingsheng Li, Weiping Xia, Guoyu Dai, Yao He, Zhi Chen
Renal fibrosis is a common pathological process that occurs with diverse etiologies in chronic kidney disease. However, its regulatory mechanisms have not yet been fully elucidated. Ferroptosis is a form of non-apoptotic regulated cell death driven by iron-dependent lipid peroxidation. It is currently unknown whether ferroptosis is initiated during unilateral ureteral obstruction (UUO)-induced renal fibrosis and its role has not been determined. In this study, we demonstrated that ureteral obstruction induced ferroptosis in renal tubular epithelial cells (TECs) in vivo. The ferroptosis inhibitor liproxstatin-1 (Lip-1) reduced iron deposition, cell death, lipid peroxidation, and inhibited the downregulation of GPX4 expression induced by UUO, ultimately inhibiting ferroptosis in TECs. We found that Lip-1 significantly attenuated UUO-induced morphological and pathological changes and collagen deposition of renal fibrosis in mice. In addition, Lip-1 attenuated the expression of profibrotic factors in the UUO model. In vitro, we used RSL3 treatment and knocked down of GPX4 level by RNAi in HK2 cells to induce ferroptosis. Our results indicated HK2 cells secreted various profibrotic factors during ferroptosis. Lip-1 was able to inhibit ferroptosis and thereby inhibit the secretion of the profibrotic factors during the process. Incubation of kidney fibroblasts with culture medium from RSL3-induced HK2 cells promoted fibroblast proliferation and activation, whereas Lip-1 impeded the profibrotic effects. Our study found that Lip-1 may relieve renal fibrosis by inhibiting ferroptosis in TECs. Mechanistically, Lip-1 could reduce the activation of surrounding fibroblasts by inhibiting the paracrine of profibrotic factors in HK2 cells. Lip-1 may potentially be used as a therapeutic approach for the treatment of UUO-induced renal fibrosis.
Kidney Int. 2019 Dec;96(6):1308-1319
[PMID:
31585741]
Nature. 2021 Jan;589(7841):281-286
[PMID:
33176333]
Cell Commun Signal. 2019 Nov 12;17(1):145
[PMID:
31718671]
Biomed Pharmacother. 2020 Jul;127:110108
[PMID:
32234642]
J Mol Cell Cardiol. 2018 Mar;116:125-134
[PMID:
29426003]
Pharmacol Rep. 2017 Aug;69(4):648-657
[PMID:
28521173]
Annu Rev Physiol. 2018 Feb 10;80:309-326
[PMID:
29068765]
Biochem Biophys Res Commun. 2019 Dec 10;520(3):606-611
[PMID:
31623831]
Cell. 2012 May 25;149(5):1060-72
[PMID:
22632970]
Nat Med. 2013 Aug;19(8):1047-53
[PMID:
23817022]
Kidney Int. 2018 Mar;93(3):568-579
[PMID:
29361307]
Biomolecules. 2019 Apr 08;9(4):
[PMID:
30965656]
Kidney Int. 2017 Nov;92(5):1071-1083
[PMID:
28890325]
ACS Cent Sci. 2018 Mar 28;4(3):387-396
[PMID:
29632885]
J Am Soc Nephrol. 2014 Dec;25(12):2689-701
[PMID:
24925726]
Kidney Int. 2018 Jan;93(1):27-40
[PMID:
29291820]
J Hematol Oncol. 2019 Mar 29;12(1):34
[PMID:
30925886]
ACS Chem Neurosci. 2019 Dec 18;10(12):4824-4833
[PMID:
31682397]
Sci Transl Med. 2019 Jan 23;11(476):
[PMID:
30674655]
Pharmacol Res. 2020 Sep;159:104919
[PMID:
32464324]
Cell Death Dis. 2018 Nov 13;9(11):1126
[PMID:
30425237]
Nat Med. 2015 Sep;21(9):989-97
[PMID:
26236989]
Cell. 2014 Jan 16;156(1-2):317-331
[PMID:
24439385]
Nat Cell Biol. 2014 Dec;16(12):1180-91
[PMID:
25402683]
Nat Rev Rheumatol. 2020 Jan;16(1):11-31
[PMID:
31792399]
Hepatology. 2016 Aug;64(2):488-500
[PMID:
27015352]
Cell Chem Biol. 2020 Apr 16;27(4):409-419
[PMID:
32275866]
Life Sci. 2019 Apr 15;223:29-37
[PMID:
30862567]
Cell Mol Life Sci. 2021 Jan;78(1):63-78
[PMID:
32596778]
Kidney Int. 2019 Sep;96(3):674-688
[PMID:
31327474]
Am J Respir Cell Mol Biol. 2020 May;62(5):554-562
[PMID:
32017592]
Cell. 2017 Oct 19;171(3):628-641.e26
[PMID:
29053969]
J Clin Invest. 2019 Nov 1;129(11):5033-5049
[PMID:
31437128]
Carbolines
Quinoxalines
RSL3 compound
Spiro Compounds
liproxstatin-1
Collagen
Iron
Phospholipid Hydroperoxide Glutathione Peroxidase
glutathione peroxidase 4, mouse